ADP-ribosylation inhibitors in treatment of diseases

Biochem Pharmacol. 2019 Sep:167:1-2. doi: 10.1016/j.bcp.2019.06.026. Epub 2019 Jun 28.

Authors

Peter Bai¹, Palmiro Poltronieri², Mariella Di Girolamo³

Affiliations

¹ University of Debrecen, Faculty of Medicine, Department of Medical Chemistry, Debrecen, Hungary. Electronic address: baip@med.unideb.hu.
² CNR-ISPA, Agrofood Department, Lecce, Italy.
³ Sol & Pharma, Teramo University, Italy.

PMID: 31255601
DOI: 10.1016/j.bcp.2019.06.026

No abstract available

Publication types

Editorial

MeSH terms

ADP-Ribosylation / drug effects*
ADP-Ribosylation / physiology
Animals
Humans
Neoplasms / drug therapy
Neoplasms / metabolism
Poly(ADP-ribose) Polymerase Inhibitors / pharmacology*
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*

Substances

Poly(ADP-ribose) Polymerase Inhibitors